Tumor-associated antigen-specific T cells (TAA-T) with PD-1 inhibitor
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Tumor-associated antigen-specific T cells (TAA-T) with PD-1 inhibitor, covering 2025-07-03 to 2025-07-03. Get the full timeline:
Most recent: Clinical Trial Update: Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma [Phase 1]